revolution medicines | Revolution Medicines

Keyword	CPC	PCC	Volume	Score	Length of keyword
revolution medicines	0.06	0.5	8905	15	20
revolution	1.87	0.7	9844	78	10
medicines	0.76	0.8	6001	13	9

Keyword	CPC	PCC	Volume	Score
revolution medicines	0.21	0.7	3873	99
revolution medicines stock	1.15	0.9	9844	47
revolution medicines careers	0.71	0.1	4140	22
revolution medicines pipeline	0.71	0.6	8918	46
revolution medicines rmc-6236	0.1	0.3	5468	54
revolution medicines kras	1.61	0.3	7113	80
revolution medicines news	1.79	0.4	8404	14
revolution medicines logo	1.88	0.9	1744	18
revolution medicines stock price	0.3	1	7495	10
revolution medicines address	1.42	0.2	9323	13
revolution medicines website	1.7	0.2	800	22
revolution medicines aktie	1.59	0.9	4096	65
revolution medicines revmed	0.73	0.3	7454	13
revolution medicines inc	1.81	1	4441	23
the ai revolution in medicine	2	0.9	1294	21
medicine in the industrial revolution	1.41	1	268	52

Search Results related to revolution medicines on Search Engine

Revolution Medicines
revmed.com

https://www.revmed.com/

WEBAt Revolution Medicines our mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines.

DA: 30 PA: 35 MOZ Rank: 1

Pipeline - Revolution Medicines
revmed.com

https://www.revmed.com/pipeline/

WEBRevolution Medicines is building a deep pipeline in support of its focus on the development and delivery of novel targeted therapies to patients with RAS-addicted cancers.

DA: 72 PA: 38 MOZ Rank: 48

Investor Relations | Revolution Medicines
revmed.com

https://ir.revmed.com/

WEBRevolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies.

DA: 95 PA: 12 MOZ Rank: 83

Revolution Medicines | LinkedIn
linkedin.com

https://www.linkedin.com/company/revolution-medicines/

WEBREVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product …

DA: 42 PA: 89 MOZ Rank: 44

Revolution Medicines: An Expensive Shot At A Massive Market …
seekingalpha.com

https://seekingalpha.com/article/4683402-revolution-medicines-stock-expensive-shot-massive-market-opportunity-hold

WEBApr 12, 2024 · Revolution Medicines raised $238 million via its 2020 IPO, and 4 years later has grown its share price by ~30%, bringing its market cap valuation to $6 billion. The company is pioneering a unique ...

DA: 45 PA: 66 MOZ Rank: 3

Revolution Medicines, Inc. to Acquire EQRx, Inc. in
globenewswire.com

https://www.globenewswire.com/news-release/2023/08/01/2715636/0/en/Revolution-Medicines-Inc-to-Acquire-EQRx-Inc-in-All-Stock-Transaction-to-Gain-More-Than-1-Billion-in-Additional-Capital.html

WEBAug 1, 2023 · REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) (Nasdaq: RVMD), a clinical-stage oncology...

DA: 95 PA: 65 MOZ Rank: 62

Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
revmed.com

https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-doses-first-patient-phase-11b-clinical-0

WEBREDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRAS G12D …

DA: 22 PA: 55 MOZ Rank: 16

Revolution Medicines Advances First RAS(ON) Inhibitor into …
revmed.com

https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-advances-first-rason-inhibitor-clinic

WEBJun 28, 2022 · Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS (ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.

DA: 80 PA: 53 MOZ Rank: 1

Glue-based KRAS inhibitors make their debut cancer trial mark
nature.com

https://www.nature.com/articles/d41573-023-00169-8

WEB23 October 2023. Glue-based KRAS inhibitors make their debut cancer trial mark. By. Asher Mullard. Revolution Medicines’ KRAS inhibitors RMC-6236 and RMC-6291 have notched up encouraging phase...

DA: 42 PA: 39 MOZ Rank: 92

About - Revolution Medicines
revmed.com

https://www.revmed.com/about/

WEBAbout - Revolution Medicines. We are Revolutionaries. At RevMed our mission is to revolutionize treatment for patients with RAS-addicted cancers through innovative, targeted medicines.

DA: 54 PA: 15 MOZ Rank: 32